Collgard Biopharmaceuticals Receives U.S. Patent for Cancer Treatment Compound

Strategic Insights -

Collgard Biopharmaceuticals, a Massachusetts-based company, has announced the receipt of a U.S. patent for the use of their lead compound, Halofuginone, in the treatment of various types of tumors. This compound, a small molecule derivative of a natural plant substance, has shown promise in inhibiting collagen production, which is essential for tumor growth and metastasis. The company plans to enter clinical trials for cancer applications in mid 2000, marking the second clinical program for Halofuginone.

Key Takeaways:

  • Collgard Biopharmaceuticals has received U.S. Patent #6,028,075 for the use of Halofuginone in treating tumors such as bladder, prostate, breast, skin, and lung cancer.
  • Halofuginone, a small molecule derivative of a natural plant substance, has demonstrated the ability to inhibit collagen production, a key factor in tumor growth and metastasis.
  • The compound has shown promise in pre-clinical testing in mouse and rat tumor models, inhibiting the progression of various types of cancer, including bladder, breast, prostate, sarcomas, and gliomas.
  • Collgard Biopharmaceuticals has six issued patents in the U.S. for major clinical applications of Halofuginone, including the treatment of scleroderma, cancer, restenosis, and fibrosis.
  • Dr. Neal Farber, Collgard Biopharmaceuticals, notes that the company is utilizing Halofuginone to treat diseases characterized by excessive collagen production, such as scleroderma and cancer.
  • The U.S. National Cancer Institute (NCI) has entered into an agreement with Collgard Biopharmaceuticals in the field of cancer therapy based on the compound's unique mechanism of action and promising pre-clinical data.

Statistics:

  • The patent granted to Collgard Biopharmaceuticals covers the use of Halofuginone in treating various types of tumors, including bladder, prostate, breast, skin, and lung cancer.
  • Halofuginone has demonstrated inhibition of collagen production, a key factor in tumor growth and metastasis, in pre-clinical testing in mouse and rat tumor models.
  • The compound has shown promise in treating various types of cancer, including bladder, breast, prostate, sarcomas, and gliomas, with a demonstrated ability to impede tumor growth and metastasis.
  • Collgard Biopharmaceuticals holds six issued patents in the U.S. for major clinical applications of Halofuginone.

Sources:

  • Collgard Biopharmaceuticals Ltd. press release, April 18, 2000.
  • Cancer Weekly, April 18, 2000, via NewsRx.com.